![Renee T. Leck](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Actieve functies van Renee T. Leck
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
ORCHARD THERAPEUTICS PLC | Investor Relations Contact | - | - |
Loopbaan van Renee T. Leck
Eerdere bekende functies van Renee T. Leck
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
AGIOS PHARMACEUTICALS, INC. | Public Communications Contact | 01-05-2015 | 01-12-2018 |
Statistieken
Internationaal
Verenigde Staten | 2 |
Verenigd Koninkrijk | 2 |
Operationeel
Public Communications Contact | 1 |
Investor Relations Contact | 1 |
Sectoraal
Health Technology | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
AGIOS PHARMACEUTICALS, INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Orchard Therapeutics Plc
![]() Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
- Beurs
- Insiders
- Renee T. Leck
- Ervaring